LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 3 of total 3

Search options

  1. Article: Sequence-to-expression approach to identify etiological non-coding DNA variations in P53 and cMYC-driven diseases.

    Kin, Katherine / Bhogale, Shounak / Zhu, Lisha / Thomas, Derrick / Bertol, Jessica / Zheng, W Jim / Sinha, Saurabh / Fakhouri, Walid D

    Research square

    2023  

    Abstract: Background and methods: Disease risk prediction based on DNA sequence and transcriptional profile can improve disease screening, prevention, and potential therapeutic approaches by revealing contributing genetic factors and altered regulatory networks. ... ...

    Abstract Background and methods: Disease risk prediction based on DNA sequence and transcriptional profile can improve disease screening, prevention, and potential therapeutic approaches by revealing contributing genetic factors and altered regulatory networks. Despite identifying many disease-associated DNA variants through genome-wide association studies, distinguishing deleterious non-coding DNA variations remains poor for most common diseases. We previously reported that non-coding variations disrupting cis-overlapping motifs (CisOMs) of opposing transcription factors significantly affect enhancer activity. We designed
    Results: Analyzing publicly available ChIP-seq data for P53 and cMYC in human embryonic stem cells and mouse embryonic cells showed that ~ 344-366 genomic regions are co-occupied by P53 and cMYC. We identified, on average, two CisOMs per region, suggesting that co-occupancy is evolutionarily conserved in vertebrates. Our data showed that treating U2OS cells with doxorubicin increased P53 protein level while reducing cMYC level. In contrast, no change in protein levels was observed in Raji cells. ChIP-seq analysis illustrated that 16-922 genomic regions were co-occupied by P53 and cMYC before and after treatment, and substitutions of cMYC signals by P53 were detected after doxorubicin treatment in U2OS. Around 187 expressed genes near co-occupied regions were altered at mRNA level according to RNA-seq data. We utilized a computational motif-matching approach to determine that changes in predicted P53 binding affinity by DNA variations in CisOMs of co-occupied elements significantly correlate with alterations in reporter gene expression. We performed a similar analysis using SNPs mapped in CisOMs for P53 and cMYC from ChIP-seq data in U2OS and Raji, and expression of target genes from the GTEx portal.
    Conclusions: We found a significant correlation between change in motif-predicted cMYC binding affinity by SNPs in CisOMs and altered gene expression. Our study brings us closer to developing a generally applicable approach to filter etiological non-coding variations associated with P53 and cMYC-dependent diseases.
    Language English
    Publishing date 2023-07-12
    Publishing country United States
    Document type Preprint
    DOI 10.21203/rs.3.rs-3037310/v1
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: The effect of non-coding DNA variations on P53 and cMYC competitive inhibition at cis-overlapping motifs.

    Kin, Katherine / Chen, Xi / Gonzalez-Garay, Manuel / Fakhouri, Walid D

    Human molecular genetics

    2016  Volume 25, Issue 8, Page(s) 1517–1527

    Abstract: Non-coding DNA variations play a critical role in increasing the risk for development of common complex diseases, and account for the majority of SNPs highly associated with cancer. However, it remains a challenge to identify etiologic variants and to ... ...

    Abstract Non-coding DNA variations play a critical role in increasing the risk for development of common complex diseases, and account for the majority of SNPs highly associated with cancer. However, it remains a challenge to identify etiologic variants and to predict their pathological effects on target gene expression for clinical purposes. Cis-overlapping motifs (COMs) are elements of enhancer regions that impact gene expression by enabling competitive binding and switching between transcription factors. Mutations within COMs are especially important when the involved transcription factors have opposing effects on gene regulation, like P53 tumor suppressor and cMYC proto-oncogene. In this study, genome-wide analysis of ChIP-seq data from human cancer and mouse embryonic cells identified a significant number of putative regulatory elements with signals for both P53 and cMYC. Each co-occupied element contains, on average, two COMs, and one common SNP every two COMs. Gene ontology of predicted target genes for COMs showed that the majority are involved in DNA damage, apoptosis, cell cycle regulation, and RNA processing. EMSA results showed that both cMYC and P53 bind to cis-overlapping motifs within a ChIP-seq co-occupied region in Chr12. In vitro functional analysis of selected co-occupied elements verified enhancer activity, and also showed that the occurrence of SNPs within three COMs significantly altered enhancer activity. We identified a list of COM-associated functional SNPs that are in close proximity to SNPs associated with common diseases in large population studies. These results suggest a potential molecular mechanism to identify etiologic regulatory mutations associated with common diseases.
    MeSH term(s) Animals ; Binding Sites ; Cell Line, Tumor ; Chromatin Immunoprecipitation/methods ; DNA/chemistry ; DNA/metabolism ; Genome, Human ; Humans ; Mice ; Mouse Embryonic Stem Cells/cytology ; Mouse Embryonic Stem Cells/metabolism ; Polymorphism, Single Nucleotide ; Proto-Oncogene Proteins c-myc/chemistry ; Proto-Oncogene Proteins c-myc/metabolism ; Regulatory Sequences, Nucleic Acid ; Tumor Suppressor Protein p53/chemistry ; Tumor Suppressor Protein p53/metabolism
    Chemical Substances MYC protein, human ; Myc protein, mouse ; Proto-Oncogene Proteins c-myc ; TP53 protein, human ; Tumor Suppressor Protein p53 ; DNA (9007-49-2)
    Language English
    Publishing date 2016-02-07
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 1108742-0
    ISSN 1460-2083 ; 0964-6906
    ISSN (online) 1460-2083
    ISSN 0964-6906
    DOI 10.1093/hmg/ddw030
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Long-term outcomes in patients with radiation-associated angiosarcomas of the breast following surgery and radiotherapy for breast cancer.

    Torres, Keila E / Ravi, Vinod / Kin, Katherine / Yi, Min / Guadagnolo, B Ashleigh / May, Caitlin D / Arun, Banu K / Hunt, Kelly K / Lam, Ryan / Lahat, Guy / Hoffman, Aviad / Cormier, Janice N / Feig, Barry W / Lazar, Alexander J / Lev, Dina / Pollock, Raphael E

    Annals of surgical oncology

    2012  Volume 20, Issue 4, Page(s) 1267–1274

    Abstract: Background: Radiation-associated angiosarcoma (RAAS) is a devastating disease occasionally observed in breast cancer patients treated with radiation. Due to its rarity, our knowledge-of disease risk factors, epidemiology, treatment, and outcome-is ... ...

    Abstract Background: Radiation-associated angiosarcoma (RAAS) is a devastating disease occasionally observed in breast cancer patients treated with radiation. Due to its rarity, our knowledge-of disease risk factors, epidemiology, treatment, and outcome-is extremely limited. Therefore, we sought to identify clinicopathologic factors associated with local and distant recurrence and disease-specific survival (DSS).
    Methods: Radiation-associated angiosarcoma was defined as pathologically confirmed breast or chest wall angiosarcoma arising within a previously irradiated field. A comprehensive search of our institutional tumor registry (1/1/93 through 2/28/11) was used to identify patients (n = 95 females). Patient, original tumor, RAAS treatment, and outcome variables were retrospectively retrieved and assembled into a database.
    Results: The median follow-up for all RAAS patients was 10.3 (range, 2.4-31.8) years. The latency period following radiation exposure ranged from 1.4 to 26 (median, 7) years. One-year and 5-year DSS rates were 93.5 and 62.6 %, respectively. Reduced risk of local recurrence was observed in patients who received chemotherapy (P = 0.0003). In multivariable analysis, size was found to be an independent predictor of adverse outcome (P = 0.015).
    Conclusions: Our study demonstrates that RAAS exhibits high recurrence rates. It also highlights the need for well-designed, multicenter, clinical trials to inform the true utility of chemotherapy in this disease.
    MeSH term(s) Adult ; Aged ; Aged, 80 and over ; Brachytherapy/adverse effects ; Breast Neoplasms/mortality ; Breast Neoplasms/pathology ; Breast Neoplasms/therapy ; Female ; Follow-Up Studies ; Hemangiosarcoma/etiology ; Hemangiosarcoma/mortality ; Hemangiosarcoma/pathology ; Humans ; Mastectomy/mortality ; Middle Aged ; Neoplasm Recurrence, Local/mortality ; Neoplasm Recurrence, Local/pathology ; Neoplasm Recurrence, Local/therapy ; Neoplasm Staging ; Neoplasms, Radiation-Induced/etiology ; Neoplasms, Radiation-Induced/mortality ; Neoplasms, Radiation-Induced/pathology ; Postoperative Complications ; Prognosis ; Survival Rate ; Time Factors
    Language English
    Publishing date 2012-12-06
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 1200469-8
    ISSN 1534-4681 ; 1068-9265
    ISSN (online) 1534-4681
    ISSN 1068-9265
    DOI 10.1245/s10434-012-2755-y
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top